DNLI - Denali Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

DNLI is currently covered by 11 analysts with an average price target of $27.48. This is a potential upside of $13.11 (91.23%) from yesterday's end of day stock price of $14.37.

Denali Therapeutics's activity chart (see below) currently has 88 price targets and 103 ratings on display. The stock rating distribution of DNLI is 95.35% BUY and 4.65% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 43.15% with an average time for these price targets to be met of 91.42 days.

Highest price target for DNLI is $45, Lowest price target is $24, average price target is $34.33.

Most recent stock forecast was given by LAURA CHICO from WEDBUSH on 07-May-2025. First documented stock forecast 01-Jan-2018.

Currently out of the existing stock ratings of DNLI, 41 are a BUY (95.35%), 2 are a HOLD (4.65%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$30

$15.63 (108.77%)

$27

4 days ago
(07-May-2025)

13/17 (76.47%)

$15.68 (109.50%)

105

Buy

$32

$17.63 (122.69%)

$87

4 days ago
(07-May-2025)

4/21 (19.05%)

$17.68 (123.46%)

111

Buy

$33

$18.63 (129.65%)

$41

2 months 4 days ago
(06-Mar-2025)

3/9 (33.33%)

$16.73 (102.83%)

382

Buy

$42

$27.63 (192.28%)

$68

2 months 8 days ago
(02-Mar-2025)

0/4 (0%)

$25.44 (153.62%)

Buy

$31

$16.63 (115.73%)

$32

3 months ago
(10-Feb-2025)

0/3 (0%)

$10.42 (50.63%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is DNLI (Denali Therapeutics) average time for price targets to be met?

On average it took 91.42 days on average for the stock forecasts to be realized with a an average price target met ratio 43.15

Which analyst has the current highest performing score on DNLI (Denali Therapeutics) with a proven track record?

MICHAEL YEE

Which analyst has the most public recommendations on DNLI (Denali Therapeutics)?

Michael Yee works at JEFFERIES and has 12 price targets and 8 ratings on DNLI

Which analyst is the currently most bullish on DNLI (Denali Therapeutics)?

Michael Yee with highest potential upside - $30.63

Which analyst is the currently most reserved on DNLI (Denali Therapeutics)?

Charles Duncan with lowest potential downside - -$0

Denali Therapeutics in the News

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you’d have done very well indeed. Having said that, unprofitable companies are risky because they could...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?